Mary Kay Continues Its Decades-Long Commitment to Skin Care Innovation With New Research on Retinol Tolerance
As one of the world’s leading innovators in skin science research for nearly six decades, Mary Kay Inc. continues its longstanding commitment to the advancement of cutting-edge skin care at the 2021 Reunión Anual de Dermatólogos Latinoamericanos (RADLA), a scientific Latin American conference. The virtual event held April 15-18 provided an opportunity for dermatology experts worldwide to exchange information on technological advances and new scientific achievements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210429005370/en/
Mary Kay was proud to share research on a gradual retinization process that significantly improves tolerance to higher concentrated pure retinol, while still delivering retinol’s key skin benefits.(Graphic: Mary Kay Inc.)
Through live and on-demand sessions, the event brought together researchers, academicians and scientists from the global dermatology community. Scientific posters and sessions unveiled the latest in skin science research and analysis. Mary Kay was proud to share research on a gradual retinization process that significantly improves tolerance to higher concentrated pure retinol, while still delivering retinol’s key skin benefits. This gradual retinization process was developed using a series of 12-week safety and clinical studies.
“Retinol is a gold standard ingredient when it comes to skin care. Beauty products containing retinol are marketed globally but higher concentration retinol products are commonly associated with potential skin irritation, stinging sensation and peeling as skin acclimates to retinol use. Through safety and clinical studies in both the United States and China, we found that a gradual retinization process can significantly improve tolerability and still provide known skin benefits associated with retinol,” said Dr. Lucy Gildea, Chief Scientific Officer at Mary Kay Inc. “We are honored to present our findings at RADLA among the world’s foremost skin care experts at this prestigious event.”
RADLA was created in 1972 due to the increasing importance and medical social responsibility of dermatology in Latin America. During the annual conference, leading skin care experts from around the world convene to exchange scientific findings on a wide range of topics in the various fields of dermatology.
“Our participation in RADLA is a tremendous opportunity to collaborate as we continue our commitment to remain at the forefront of advancements in skin health,” said Dr. Lucy Gildea. “It’s one of a series of partnerships with the scientific and academic communities to further expand Mary Kay’s leadership in science-based product development as we continue to provide the highest quality products to our Mary Kay Independent Beauty Consultants and brand lovers worldwide.”
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company nearly 60 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005370/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
L&T Technology Services Transforms Respiratory Diagnostics with NVIDIA AI-Powered Digital Twin Technology1.12.2025 09:30:00 EET | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & R&D Consulting Services, today announced the development of a next-gen AI-powered digital twin platform for respiratory diagnostics and lung navigation. Combining LTTS’ expertise in platform engineering, AI-driven diagnostics, connected health systems and advanced imaging and visualization with cutting-edge NVIDIA AI infrastructure, LTTS aims to deliver scalable, low-latency solutions that enhance diagnostic precision and improve accessibility for healthcare providers worldwide. To be unveiled at the Radiological Society of North America (RSNA) 2025, the LTTS solution integrates with CT imaging and leverages deep learning models to create a 3D digital twin of lung anatomy, providing visualization of airways, blood vessels, lung lobes and lesions. Powered by NVIDIA MONAI for medical image segmentation and NVIDIA TensorRT for optimized AI inference, the biological digital twin enables interactive visualiza
Regnology Completes Acquisition of Wolters Kluwer’s Finance, Risk & Regulatory Reporting Business1.12.2025 09:00:00 EET | Press release
Regnology, a global leader in regulatory reporting and supervisory technology, today announces the successful closing of its acquisition of Wolters Kluwer’s Finance, Risk & Regulatory Reporting (FRR) business. This milestone reinforces Regnology’s position as the trusted partner for financial institutions and regulators worldwide, delivering smarter, faster compliance solutions at scale. Regnology is committed to ensuring business continuity for all FRR clients. With a proven track record in seamless migrations and a unified data model on a scalable SaaS platform, institutions can maintain compliance securely and efficiently throughout the integration process. The acquisition underscores Regnology’s vision to combine regulatory expertise with innovation. The recently launched RRH Ascend platform exemplifies this commitment, offering cloud-native architecture, advanced automation, and AI-driven insights to transform regulatory data into strategic value. By integrating Wolters Kluwer’s F
Ant International Upgrades Antom Copilot to Advance Domain-Specific Agentic AI to Solve Global Payment Complexity1.12.2025 08:21:00 EET | Press release
Antom, a leading merchant payment and digitisation services provider under Ant International, today announced major upgrades to Antom Copilot, its industry-first AI agent designed for merchant payment and operations management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251130027598/en/ Antom Copilot supports a wide range of merchant payment operations and responds to early signs of issues with tailored recommendations. Integrated into the Antom Merchant Portal, Antom Copilot now provides enhanced automation and tailored assistance based on learnings from real-world cases, to help merchants handle payment complexity more efficiently. Main features include: Agentic support for entire payment lifecycle, from onboarding and integration, to dispute handling, risk control and payment success rate operation; Domain-trained intelligence functions like a virtual team of payment experts to manage traditionally resource-intensive
Samsung Bioepis Announces Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe1.12.2025 08:00:00 EET | Press release
Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. The products will be commercially available in Europe in December 2025 and January 2026, respectively. “We are very thrilled to launch OBODENCE and XBRYK through our direct sales efforts. Osteoporosis remains a major challenge in Europe due to limited treatment options and affordability challenges. And bone-related events resulting from bone metastases significantly impact a patient's quality of life, leading to death if not treated fast enough. Our biosimilars aim to improve access, enable timely care, and ease the financial burden on healthcare systems.”, said Linda Choi MacDonald, Executive Vice President and Global Head of Commercial Division at Samsung Bioepis. “With our proven track records, we’re confident that OBODENCE and XBRYK will deliver meaningful impact on patients and their communities.” OBODENCE, refer
UAE announces Google Gemini Is Now the Most Culturally Accurate AI for Arabs28.11.2025 23:31:00 EET | Press release
The UAE’s Artificial Intelligence, Digital Economy, and Remote Work Applications Office announced that Google Gemini has ranked first in the “AI in the Ring” Index, the world’s first benchmark designed to evaluate how effectively AI language models reflect Emirati culture, dialects, traditions, and national values through a challenge centered on cultural intelligence within the UAE context. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251128785463/en/ UAE announces Google Gemini Is Now the Most Culturally Accurate AI for Arabs (Photo: AETOSWire) Gemini earned the top ranking following a review of over 400 questions across 7 cultural dimensions and 5,200 generated responses from 11 major language models. A Committee of Emirati experts evaluated the outputs to identify which models demonstrated the strongest cultural understanding. Following Gemini 2.5 Pro, the list of the top five high-performing models included: ChatGPT (O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom